Latest Insider Transactions at Compass Therapeutics, Inc. (CMPX)
This section provides a real-time view of insider transactions for Compass Therapeutics, Inc. (CMPX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Compass Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Compass Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 10
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
24,447
+0.17%
|
$24,447
$1.6 P/Share
|
|
May 09
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
90,712
+0.62%
|
$90,712
$1.56 P/Share
|
|
May 09
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
90,712
+0.62%
|
$90,712
$1.56 P/Share
|
|
May 06
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
10,200
+0.07%
|
$10,200
$1.63 P/Share
|
|
May 06
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
10,200
+0.07%
|
$10,200
$1.63 P/Share
|
|
Nov 16
2021
|
Vered Bisker Leib CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+35.02%
|
-
|
|
Nov 16
2021
|
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+10.48%
|
-
|
|
Nov 04
2021
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
5,357,143
+30.48%
|
$16,071,429
$3.5 P/Share
|
|
Nov 04
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
5,357,143
+30.48%
|
$16,071,429
$3.5 P/Share
|
|
Jun 25
2021
|
Miranda Jayne Toledano Director |
BUY
Other acquisition or disposition
|
Direct |
1,791,549
+50.0%
|
-
|
|
Jun 19
2020
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Direct |
1,455,132
+10.27%
|
$7,275,660
$5.0 P/Share
|